PORTFOLIO COMPANIES
-
commercialization of innovative products based on revolutionary discoveries in the field of immunology
-
patented drug delivery technologies
-
dedicated to the development and commercialization of personalized cancer immunotherapies
-
prevention, treatment, rescue and recovery of neurodegenerative and neurovascular diseases
ABOUT THE HCG
HCG has been focused exclusively on organizing, funding, developing, and commercializing "disruptive" healthcare technologies We used a shared services business model to bring expertise honed from years of start-up experience in a cost-effective manner to each portfolio company. We are long-term investors with a timeline more like a perpetual institutional investor. Our limited partners are exclusively ultra-high net worth individuals, families, and trusts whom we know personally and who share our passion for investing in a sector where the economic benefits are supplemented by meaningful contributions to healthcare. Learn More.
HOPKINS CAPITAL AND ACCENTIA BIOPHARMACEUTICALS
Accentia Biopharmaceuticals, Inc is intended to be our primary vehicle for making future investments in disruptive healthcare technologies. We engineered ABPI to have the critical competencies in the areas of the identification, due diligence, evaluation, in-licensing, development, and commercialization of new technologies. Accordingly, HCG has distributed to its limited partners interests in publicly-traded holdings, and it is not making new direct investments in healthcare.
LATEST NEWS
Accentia's Revimmune at Johns Hopkins University: High Time for HiCy? (January 2008)
Accentia Biopharmaceuticals (NASDAQ:ABPI)